BioMarin Pharmaceutical Inc. - Product Pipeline Review - 2015

  • ID: 3266315
  • Company Profile
  • 97 pages
  • Global Markets Direct
  • BioMarin Pharmaceutical Inc.
1 of 4
BioMarin Pharmaceutical Inc. - Product Pipeline Review - 2015

Summary

This, ‘BioMarin Pharmaceutical Inc. - Product Pipeline Review - 2015’, provides an overview of the BioMarin Pharmaceutical Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of BioMarin Pharmaceutical Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of BioMarin Pharmaceutical Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of BioMarin Pharmaceutical Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the BioMarin Pharmaceutical Inc.’s pipeline products

Reasons to buy

- Evaluate BioMarin Pharmaceutical Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of BioMarin Pharmaceutical Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the BioMarin Pharmaceutical Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of BioMarin Pharmaceutical Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of BioMarin Pharmaceutical Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of BioMarin Pharmaceutical Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables
List of Figures
BioMarin Pharmaceutical Inc. Snapshot
BioMarin Pharmaceutical Inc. Overview
Key Information
Key Facts
BioMarin Pharmaceutical Inc. - Research and Development Overview
Key Therapeutic Areas
BioMarin Pharmaceutical Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
BioMarin Pharmaceutical Inc. - Pipeline Products Glance
BioMarin Pharmaceutical Inc. - Late Stage Pipeline Products
Pre-Registration Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
BioMarin Pharmaceutical Inc. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Phase 0 Products/Combination Treatment Modalities
BioMarin Pharmaceutical Inc. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
BioMarin Pharmaceutical Inc. - Unknown Stage Pipeline Products
Unknown Products/Combination Treatment Modalities
BioMarin Pharmaceutical Inc. - Drug Profiles
drisapersen
Product Description
Mechanism of Action
R&D Progress
elosulfase alfa
Product Description
Mechanism of Action
R&D Progress
sapropterin dihydrochloride
Product Description
Mechanism of Action
R&D Progress
amifampridine phosphate
Product Description
Mechanism of Action
R&D Progress
pegvaliase
Product Description
Mechanism of Action
R&D Progress
reveglucosidase alfa
Product Description
Mechanism of Action
R&D Progress
talazoparib
Product Description
Mechanism of Action
R&D Progress
BMN-044
Product Description
Mechanism of Action
R&D Progress
BMN-045
Product Description
Mechanism of Action
R&D Progress
BMN-111
Product Description
Mechanism of Action
R&D Progress
cerliponase alfa
Product Description
Mechanism of Action
R&D Progress
BMN-053
Product Description
Mechanism of Action
R&D Progress
RG-2833
Product Description
Mechanism of Action
R&D Progress
Antisense RNAi Oligonucleotides to Activate Dysferlin for Dysferlinopathies
Product Description
Mechanism of Action
R&D Progress
BMN-250
Product Description
Mechanism of Action
R&D Progress
BMN-270
Product Description
Mechanism of Action
R&D Progress
PRO-052
Product Description
Mechanism of Action
R&D Progress
PRO-055
Product Description
Mechanism of Action
R&D Progress
PRO-135
Product Description
Mechanism of Action
R&D Progress
PRO-289
Product Description
Mechanism of Action
R&D Progress
PROSPECT
Product Description
Mechanism of Action
R&D Progress
RG-3250
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Sanfilippo Syndrome
Product Description
Mechanism of Action
R&D Progress
Antisense RNAi Oligonucleotide for Rheumatoid Arthritis
Product Description
Mechanism of Action
R&D Progress
RNAi Oligonucleotide for Bone Diseases
Product Description
Mechanism of Action
R&D Progress
RNAi Oligonucleotide for Cancer
Product Description
Mechanism of Action
R&D Progress
RNAi Oligonucleotide for Skin Diseases
Product Description
Mechanism of Action
R&D Progress
BioMarin Pharmaceutical Inc. - Pipeline Analysis
BioMarin Pharmaceutical Inc. - Pipeline Products by Target
BioMarin Pharmaceutical Inc. - Pipeline Products by Route of Administration
BioMarin Pharmaceutical Inc. - Pipeline Products by Molecule Type
BioMarin Pharmaceutical Inc. - Pipeline Products by Mechanism of Action
BioMarin Pharmaceutical Inc. - Recent Pipeline Updates
BioMarin Pharmaceutical Inc. - Dormant Projects
BioMarin Pharmaceutical Inc. - Dormant Projects
BioMarin Pharmaceutical Inc. - Company Statement
BioMarin Pharmaceutical Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
BioMarin Pharmaceutical Inc. - Key Manufacturing Facilities
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
BioMarin Pharmaceutical Inc., Key Information
BioMarin Pharmaceutical Inc., Key Facts
BioMarin Pharmaceutical Inc. - Pipeline by Indication, 2015
BioMarin Pharmaceutical Inc. - Pipeline by Stage of Development, 2015
BioMarin Pharmaceutical Inc. - Monotherapy Products in Pipeline, 2015
BioMarin Pharmaceutical Inc. - Pre-Registration, 2015
BioMarin Pharmaceutical Inc. - Phase III, 2015
BioMarin Pharmaceutical Inc. - Phase II, 2015
BioMarin Pharmaceutical Inc. - Phase I, 2015
BioMarin Pharmaceutical Inc. - Phase 0, 2015
BioMarin Pharmaceutical Inc. - Preclinical, 2015
BioMarin Pharmaceutical Inc. - Discovery, 2015
BioMarin Pharmaceutical Inc. - Unknown, 2015
BioMarin Pharmaceutical Inc. - Pipeline by Target, 2015
BioMarin Pharmaceutical Inc. - Pipeline by Route of Administration, 2015
BioMarin Pharmaceutical Inc. - Pipeline by Molecule Type, 2015
BioMarin Pharmaceutical Inc. - Pipeline Products by Mechanism of Action, 2015
BioMarin Pharmaceutical Inc. - Recent Pipeline Updates, 2015
BioMarin Pharmaceutical Inc. - Dormant Developmental Projects,2015
BioMarin Pharmaceutical Inc., Other Locations
BioMarin Pharmaceutical Inc., Subsidiaries
BioMarin Pharmaceutical Inc., Key Manufacturing Facilities

List of Figures
BioMarin Pharmaceutical Inc. - Pipeline by Top 10 Indication, 2015
BioMarin Pharmaceutical Inc. - Pipeline by Stage of Development, 2015
BioMarin Pharmaceutical Inc. - Monotherapy Products in Pipeline, 2015
BioMarin Pharmaceutical Inc. - Pipeline by Top 10 Target, 2015
BioMarin Pharmaceutical Inc. - Pipeline by Top 10 Route of Administration, 2015
BioMarin Pharmaceutical Inc. - Pipeline by Top 10 Molecule Type, 2015
BioMarin Pharmaceutical Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll